Chief Operating Officer
Keith Dredge is a drug development consultant with over 20 years of experience, including executive positions in Zucero Therapeutics, Paragen Bio, Progen Pharmaceuticals, TetraQ, and consulting for a number of biotech companies in Australia. Major achievements include the development of the immunomodulator pixatimod from conception to a Phase 2 clinical trial in the U.S. and the design of the preclinical testing cascade for Revlimid® and Pomalyst®, now FDA-approved immunomodulatory drugs for cancer. Keith has authored 50 scientific publications and is an inventor on two patent applications. Keith has a B.Sc. (Hons) in Toxicology and PhD in Pharmacology from the National University of Ireland, Galway, and was a UK and European Registered Toxicologist (ERT) from 2008-2015.